Renovorx announces presentation of final data from rr2 observational registry study at 2021 pancreas club annual meeting

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will be presenting an eposter at the 2021 pancreas club annual meeting being held virtually on november 11-12, 2021. the poster describes the rr2 observational registry study, which used renovorx's novel therapy platform, renovotamp™ (renovorx trans-arterial micro-perfusion), to deliver gemcitabine, an approved chemotherapeutic agent, i
RNXT Ratings Summary
RNXT Quant Ranking